Podcasts about Merck

In this deeply personal episode of Shifting Dimensions, Jummie speaks with artist, architect, and storyteller Ksenia Merck about love, loss, grief, and the ways connection can continue beyond physical death.Ksenia shares the story of her late husband, Bill, their relationship, his final months, and how completing and illustrating his science fiction novel Ghost Flower became part of her own healing journey. Their creative collaboration continued after his passing, helping Ksenia explore grief, spirituality, the afterlife, and the possibility that love truly transcends dimensions.The conversation also explores the healing power of art, spiritual curiosity, animal companionship, presence, and what grief can teach us about cherishing the people we love while they are still here.Where to find Ksenia: Website: https://www.merckiipress.com/ LinkedIn: https://www.linkedin.com/in/ksenia-merck-44525514/ Facebook: https://www.facebook.com/merck2press Instagram: https://www.instagram.com/merck2press/ Send us Fan MailSupport the showLove the show? Your support helps keep these conversations going. You can treat me to a coffee here:https://buymeacoffee.com/shiftingdimensionsSubscribe to our YouTube channel: https://www.youtube.com/channel/UCr0p1zDPaPLmnmI3AIWhDFQFollow us: TikTok -  @shiftingdimensions444  Instagram -  @shiftingdimensions_podDisclaimer: The views, thoughts, and opinions expressed are the guest's own and do not represent the views, thoughts, and opinions of Shifting Dimensions. The material and information presented here is for general information and entertainment purposes only. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

MAPS Chief Medical Officer Charlotte Kremer sits down with Dr. Bjorn Oddens, Senior Vice President, Value and Implementation at Merck, for a candid conversation on the career-defining moments, hard-won lessons, and mentors that shaped his path — plus his view on where Medical Affairs is headed over the next decade. About the Medical Affairs Professional Society (MAPS)The Medical Affairs Professional Society (MAPS) is the leading global authority and community for Medical Affairs professionals, uniting over 18,000 members across 400+ organizations in Pharmaceutical, Biotech, MedTech, and related industries. Founded in 2016, MAPS is a 501(c)(3) nonprofit dedicated to advancing careers and elevating the Medical Affairs profession worldwide. 

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data. Finally, Peter and Michael explore the benefits of omega-3 fatty acids and the challenge of delivering DHA to the brain, as well as ongoing work on klotho in preparation for clinical trials. They discuss the potential for AI to transform clinical trials and the scientific and financial challenges of developing new therapies for cardiovascular and neurodegenerative disease. We discuss: Michael's path to lipidology, and his passion for primary prevention [3:30]; Reframing prevention around causal drivers rather than time horizon [9:30]; What CETP inhibition does, the evolutionary biology of CETP, the HDL-raising rationale, and Pfizer's torcetrapib failure [15:00]; Why raising HDL is thought to be beneficial, a quick review of the functions of HDL, and how this connects to torcetrapib [24:00]; The graveyard of CETP inhibitors: Roche's dalcetrapib, Lilly's evacetrapib, and Merck's REVEAL trial [27:15]; The causality of LDL in cardiovascular disease [34:30]; Reviving obicetrapib at NewAmsterdam, and confirming the benefit is LDL lowering: the TULIP data, the abandoned statin-intolerance path, and the Mendelian randomization verdict on HDL [37:30]; Phase 2 and phase 3 trials of obicetrapib—ROSE, BROOKLYN, BROADWAY, and TANDEM—and the PREVAIL outcomes trial, with the European and US approval paths [44:45]; Discordance among LDL-C, LDL-P, and apoB with CETP inhibition, and obicetrapib's Lp(a)-lowering effect [50:30]; Where obicetrapib fits in the lipid-lowering toolkit, the case against high-dose statins, and the problem of drug pricing [57:30]; The case for obicetrapib in Alzheimer's: the APOE4 and CETP genetics, the animal models, and funding Alzheimer's research [1:03:45]; Brain cholesterol metabolism and the APOE4 mechanism: the blood-brain barrier, astrocyte cholesterol efflux, the amyloid-tau cascade, the role of HDL, and why statins don't cause Alzheimer's disease [1:08:00]; The biomarker evidence: the CSF pilot study, Alzheimer's as a disease of middle age, the pharma graveyard problem, and the p-tau 217 results from BROADWAY [1:17:45]; Whether obicetrapib translates into clinical benefit for Alzheimer's disease: the risk of fooling yourself, the persistence of the amyloid dogma, ARIA in APOE4 homozygotes, and the next prevention trial [1:28:00]; Fish oil, EPA, and DHA: the cardiovascular trials and the challenge of delivering DHA to the brain [1:32:00]; Two open problems: using AI to reform clinical trials, and the statin–diabetes signal [1:41:15]; What it takes to develop a drug, the biotech investment landscape, and the klotho program [1:48:15]; Closing reflections: what to do if you carry APOE4, balancing motivation against over-testing, and the need for multiple therapies [1:55:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are implicated in diseases like cancer and neurodegenerative disorders. However, their smooth protein surfaces present a challenge for traditional small molecule drugs, which struggle to find suitable binding pockets. Similarly, biologics like antibodies and peptides, despite their high binding affinities, face difficulties penetrating cell membranes due to their size and instability. Grove Biopharma addresses these issues through its proprietary Bionics Biologics™ technology. Developed by Nathan Gianneschi at Northwestern University, this approach uses protein-like polymers to mimic proteins with enhanced stability and cellular penetration. These polymers, adorned with peptide branches via living polymerization, maintain peptide binding properties while overcoming previous limitations in drug delivery. This breakthrough has already shown promise in preclinical studies. A 2023 study in Science Advances revealed the efficacy of targeting membrane protein CD36 for treating macular degeneration in mice, while a 2024 study demonstrated PLPs' ability to penetrate neurons and target mitochondria in Huntington's disease models. Moreover, a 2026 Nature Communications publication introduced HYDRAC, a new PLP class capable of degrading MYC and KRAS proteins, reducing tumor growth in mice. Grove Biopharma's pipeline is robust, targeting key areas in cancer and neurodegeneration. Despite challenges typical of the biotech landscape—such as toxicity concerns during clinical trials and scalability issues—Grove's unique platform offers the flexibility needed to address multiple targets effectively. Shifting focus to industry-wide developments, recent advancements highlight significant strides in personalized medicine. Moderna and Merck's mRNA cancer vaccine has shown promising results in a phase 3 study, marking an important step forward for customized healthcare approaches based on genetic profiles. This not only offers hope for cancer treatment but also signifies a wider shift towards more tailored therapeutic strategies. Regulatory updates also play a critical role in shaping industry dynamics. The appointment of Dr. Angelo De Claro as chief of the FDA Oncology Center of Excellence is pivotal. His focus on modernizing regulatory practices aims to expedite drug approvals while ensuring that innovative treatments reach patients more swiftly. However, the FDA's decision to delay approval for Exelixis' tyrosine kinase inhibitor with Roche's Tecentriq underscores the complexities involved in novel therapies' assessments. On the geographical front, Singapore's launch of a biotech hub in Boston highlights the global nature of biotech development. This move strengthens historical ties and emphasizes international collaboration's importance in accelerating scientific research. In clinical trials, AbbVie's success with Qulipta (atogepant) for menstrual migraine prevention is noteworthy. It not only expands therapeutic options for women but also underscores a growing focus on gender-specific health issues within clinical research. Meanwhile, new RAS-targeting therapies continue to emerge as Revolution Medicines' Rasonque gains approval for advanced pancreatic cancer treatment—a significant milestone in addressing previously undruggable mutations. Industry dynamics are further illustrated by leadership changes at major firms like Takeda. The departure of long-time R&D chief Andy Plump often signals strategic shifts that could influence research priorities and corporate focus. Novartis recently faced setbacks with late-stage asset failures impacting its market position and raising investor concerns about its strategic direction concerning mergers and acquisitions. On a similar note, Takeda undergoes organizational changes amid potential strategic shifts following its CEO appointment—demonstrating volatility within companies striving for competitive advantage through effective leadership. Promising developments at the FDA include solidifying leadership with Karim Mikhail at CBER and Michael Davis at CDER—crucial appointments ensuring operational stability amidst past disruptions under former commissioner Marty Makary—and appointing Jared Seehafer as deputy commissioner focusing on AI integration into regulatory processes. Significant financial movements continue highlighting investor interest: Frazier adds over $1 billion targeting small-mid-sized biotech firms while Samsung Biologics secures manufacturing deals emphasizing strategic partnerships' importance globally. Scientific developments also reveal challenges; Silence Therapeutics maintains polycythemia vera leadership despite emerging hurdles while Novo Nordisk halts heart disease studies reflecting complexities validating interleukin-6 as therapeutic targets. AI integration gains momentum transforming operational efficiencies across various functions from R&D to human resources optimizing overall effectiveness within life sciences organizations—a trend poised to reshape people strategy profoundly impacting medical affairs evidenced evaluations enhancing decision-making processes ultimately improving patient outcomes significantly moving forward amidst this dynamic industry landscape filled with opportunities and risks requiring agility and forward-thinking strategies to capitalize on emerging scenarios efficiently and effectively ensuring continued success thriving amidst transformations occurring rapidly around us today, tomorrow, and beyond!Support the show

For many people living with inflammatory bowel disease (IBD), understanding what remission actually means can be confusing. If your symptoms improve, does that mean your IBD is under control? And if you're in remission, is the disease gone for good? In Part 2 of our conversation with IBD expert Dr. Jessica Allegretti, we explore what remission means in IBD and why feeling better is only one part of the picture. We discuss: Clinical remission versus endoscopic remission What mucosal healing means The treat-to-target approach in IBD care Why modern treatment goals focus on long-term disease control How controlling inflammation may help reduce the risk of future complications Understanding both how you feel and what may be happening inside your body can help you have more informed conversations with your healthcare team and take an active role in managing your IBD. Subscribe to Gastro Girl for more expert-led conversations designed to help you navigate digestive health with confidence. This educational initiative is sponsored by Merck.  

Kelli Hoffman, co-executive director of the Noblesville nonprofit Healthy & Dwell, joins Larry Lannan to discuss what adults with serious mental illness face when they leave treatment and have nowhere stable to live. Healthy & Dwell operates a supportive housing home in Noblesville where residents pay 30% of their income toward rent and utilities and receive life-skills coaching and help navigating benefits — a model Hoffman says has kept residents employed, connected and out of acute care for three years. The organization is privately funded and is now building duplexes to expand. Larry opens with commentary on why housing insecurity and mental illness are easy to overlook in a prosperous county, and why a discharge plan is not the same thing as a safe place to sleep. Also in this episode: the first successful late-stage trial of a personalized mRNA cancer vaccine from Merck and Moderna, and a South Carolina man with more than 2,000 pairs of socks chasing a Guinness World Record. Learn more: healthyanddwell.org More local news: larryinfishers.com Sponsored by Citizens State Bank — mycsbin.com/larry. Member FDIC. Equal Housing Lender.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating updates that are shaping the future of medicine and patient care. First on our agenda is uniQure's ambitious step toward accelerated U.S. marketing approval for AMT-130, a gene therapy targeting Huntington's disease. This move signifies a potential breakthrough in treating rare neurological disorders with genetic roots. The approval of AMT-130 would highlight gene therapy's transformative power, not just for Huntington's disease but also for a broader range of genetic conditions, offering hope to patients where traditional treatments have fallen short. In the realm of oncology, Summit Therapeutics, in collaboration with Akeso, has reported that their bispecific antibody ivonescimab has surpassed Merck's Keytruda in a Phase 3 trial for non-small cell lung cancer. The trial revealed superior overall survival and progression-free survival rates, marking a significant milestone in cancer treatment. Bispecific antibodies like ivonescimab open new avenues for targeting multiple pathways simultaneously, potentially leading to more effective therapies with reduced side effects. Collaboration continues to be a pivotal strategy in drug development. GSK and Hutchmed have formed a licensing agreement for HMPL-A830, an innovative cancer therapy. This partnership involves an upfront payment of $110 million, with the potential to reach $1.3 billion based on performance milestones. Such alliances highlight the importance of strategic partnerships in accelerating therapeutic advancements and expanding the arsenal of available cancer treatments. Moving to regulatory milestones, Samsung Bioepis has secured approval in Japan for its biosimilar ustekinumab, aimed at treating moderate-to-severe Crohn's disease by targeting IL-12/IL-23 pathways. This approval is part of a larger trend towards biosimilars as cost-effective alternatives to biologics, increasing access to essential treatments for autoimmune diseases. In cardiovascular health, Everest Medicines has received China NMPA approval for Cardamyst (etripamil), a self-administered nasal spray for paroxysmal supraventricular tachycardia. The approval underscores innovations in patient-centric drug delivery systems that offer easier administration methods and empower patients to manage their conditions effectively. On the business front, Fortrea has acquired Worldwide Clinical Trials' early-phase division for $45 million. This acquisition aims to bolster Fortrea's clinical research organization platform, reflecting the growing demand for comprehensive clinical pharmacology services that can accelerate drug development timelines. Meanwhile, Pfizer's divestment of its Seagen antibody-drug conjugate PF-08046031 to Medicus Pharma in a deal exceeding $1 billion exemplifies strategic realignments within large pharmaceutical companies. These transactions allow companies to streamline operations and focus on core therapeutic areas where they can make the most impact. Research advancements are also making headlines as Revolution Medicines reports promising Phase 1/2 data for Rasonque (daraxonrasib) in NSCLC patients with KRAS mutations. KRAS has been notoriously difficult to target, so these findings highlight Rasonque's potential as a breakthrough small molecule therapy addressing critical needs in oncology. Despite these strides forward, challenges remain evident. Ultragenyx's GTX-102 did not meet primary or secondary endpoints in its Phase 3 Angelman syndrome study. This setback highlights the complexities involved in developing effective treatments for rare neurological conditions and underscores the inherent risks in high-stakes clinical trials. Turning our attention back to regulatory dynamics, FDA deliberations over Replimune's melanoma treatment revealed nuanced decision-making processes balancing clinical evaluation with strategic considerations. Even amidst internal disagreements, FDA leadership endorsed an accelerated nod for Replimune's therapy—an illustration of how complex these processes can be. In terms of funding innovation, ARPA-H's substantial $125 million investment into personalized RNA-based drug production reflects a commitment to advancing RNA therapeutics despite recent challenges. The initiative could become a catalyst for new approaches in personalized medicine by leveraging RNA technologies to tailor treatments more precisely to individual profiles. Additionally, Roche is making headway in obesity treatment with its UCN2 analog, which shows promise in reducing weight without sacrificing lean muscle mass—an essential factor given obesity's global health implications. This development may introduce new mechanisms of action that could revolutionize existing therapies by overcoming metabolic challenges inherent in obesity treatment. Overall, these developments underscore a dynamic period within the pharmaceutical and biotech sectors characterized by rapid scientific progress and strategic realignments responding to evolving market demands. As companies navigate these changes, their ability to leverage new technologies and refine their strategic focus will be crucial in maintaining competitive advantage and driving future growth—all while aiming to improve patient outcomes globally.Support the show

A new mRNA vaccine for melanoma is making headlines. Moderna and Merck recently announced results from their clinical trial suggesting that this new vaccine, in combination with the cancer drug Keytruda, reduced recurrence rates in patients. The companies have not yet released full data from the trial. So, how does the vaccine work? And does this mark the beginning of a new era of cancer treatments using mRNA vaccine technology? Ira talks with physician Michael Postow, whose patients were part of the drug trial at Memorial Sloan Kettering Cancer Center. Guest: Dr. Michael Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center. Transcript will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thu, 03 Sep 2026 23:42:00 GMT http://relay.fm/roboism/81 http://relay.fm/roboism/81 Kathy Campbell and Alex Cox Goodbye, Dolly. ♥️ (This is a happy one though! There's also some robots, sports, and animated crushes! Don't worry!) Goodbye, Dolly. ♥️ (This is a happy one though! There's also some robots, sports, and animated crushes! Don't worry!) clean 2859 Goodbye, Dolly. ♥️ (This is a happy one though! There's also some robots, sports, and animated crushes! Don't worry!) Links and Show Notes: Relay for St. Jude The 2026 World Humanoid Robot Games Robot Riot: Chicago's robot fighting league BattleBots Portland Fire mascot Rose, the glitter-breathing dragon Chicago Sky CARROT Weather Dolly Parton Tim Curry Conduit #135: “It's Better With A Friend” Can Can's Dolly! at Portland's Paris Theatre Dolly Parton's funding of COVID-19 vaccine research at Vanderbilt Moderna and Merck's mRNA cancer vaccine breakthrough Dollywood Dolly Parton's 1977 interview with Barbara Walters Dolly Parton's longtime support of her trans friend and employee Jason Pirro Dolly Parton on Black Lives Matter Dolly Parton investing Whitney Houston's “I Will Always Love You” royalties in a Black Nashville neighborhood Dolly Parton's Imagination Library Dolly Parton – “Family” Dolly Parton on same-sex marriage: “They should suffer like the rest of us do” Dolly Parton denounces North Carolina's anti-trans bathroom bill The Three Musketeers (1993) The Rocky Horror Picture Show Clue The Beaverton: “Tim Curry's death to be investigated by suspicious group of eccentrics gathering at his house” Tim Curry as Premier Cherdenko in Command & Conquer: Red Alert 3 FernGully: The Last Rainforest The “Hear Me Out Cake” trend The Hunchback of Notre Dame Disney's Robin Hood Balto Chicago Cubs Chicago Stars FC Chicago Fire FC The Unicorn Sidekick The Unicorn Sidekick on YouTube Conduit Kathy Campbell Alex Cox Support Roboism with a Relay Membership

This CEO is Fighting Parkinson's And Other Neuro-Degenerative Diseases – Meet Gain Therapeutics GANX CEOGuest: Gene Mack, CEO, Gain TherapeuticsGuest's Bio: Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the Company in April 2024 and brings 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing, corporate strategy and business development. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. Previous to Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck & Co's (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO. Before that, he has held the CFO role for several development- and commercial-stage biopharmaceutical companies, raising over $350 million in IPO and other equity transactions. Prior to his operational experience, Gene covered the biotechnology and life sciences sector as a senior publishing analyst at various investment banks, including Gruntal & Co, Lazard, Mizuho, and HSBC. Gene received both his B.S. in Biochemistry and M.B.A. in Finance from Fordham University.Company: Gain Therapeutics ($GANX)Company Description: Gain Therapeutics, a clinical-stage biotechnology company headquartered in Bethesda focused on developing novel allosteric small molecule therapies for neurodegenerative diseases.Under Gene's leadership, the company is advancing its lead candidate, GT-02287, with recent Phase 1b data presented at AD/PD 2026 demonstrating encouraging biomarker improvements, including reductions in DDC and glucosylsphingosine, as well as durable clinical outcomes through 150 days of treatment in Parkinson's disease.

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck's individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient's tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna's longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck's individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient's tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna's longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über den gruseligen September-Auftakt, Kracherzahlen von Dell und eine Enzym-Aktie, die fremde Blockbuster in eigene Erlöse verwandelt. Außerdem geht es um SAP, CrowdStrike, Cloudflare, RWE, Merck, Apple, Credo Technology, MongoDB, GitLab, Palo Alto Networks, Nvidia, Broadcom, Shein, H&M, Fast Retailing, Next, Inditex, Associated British Foods (ABF), Gap, Roche, Johnson & Johnson, Merck & Co., Halozyme Therapeutics, Bristol-Myers Squibb, Pfizer, Eli Lilly, Alteogen, Schott Pharma, Gerresheimer, Ypsomed, West Pharmaceutical Services, Husqvarna, Toro, KraneShares Global Humanoid and Embodied Intelligence ETF (WKN: A41PZ8) und iShares Automation & Robotics ETF (WKN: A2ANH0). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3… Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

What if we could reverse the damage caused by age-related disease instead of simply managing its symptoms? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Daniel Oliver, CEO and Co-founder of Rejuvenate Bio, a Jetstream Venture Fund portfolio company, to explore the science behind age-related disease, the potential of gene therapy, and what it takes to turn groundbreaking research into treatments for both animal and human health. This success has lead to one of the leading crowdfunding equity campaigns.Rejuvenate Bio grew out of George Church's lab at Harvard Medical School, where research into the biology of aging opened the door to a bigger question: instead of treating age-related diseases one at a time, could we target the underlying changes that drive them? Daniel explains the company's work across heart failure, kidney failure, metabolic dysfunction, and epigenetic reprogramming. Daniel and John also dig into Rejuvenate Bio's strategy of developing therapies for both companion animals and humans. Its most advanced program is targeting mitral valve disease in dogs, while its human program moves toward clinical development. Daniel explains why dogs can be a powerful model for age-related disease and how animal health may provide a faster path for translating aging science into real-world therapies. Beyond the science, Daniel shares his unconventional journey from mechanical engineering and aerospace to Harvard Business School, entrepreneurship, and biotech. He and John discuss why breakthrough ideas often emerge at the intersection of different disciplines, and they get candid about the pressure of startup life and why the “never sleep, always hustle” mentality can make founders worse leaders. About Daniel Oliver: Daniel Oliver is Co-founder and CEO of Rejuvenate Bio, a spinout of George Church's Lab at Harvard Medical School focused on targeting the drivers of age-related disease through novel gene therapies. Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship, during which he co-founded Voxel8. Voxel8 was named one of the top innovations at CES and one of the 50 most innovative companies by MIT Technology Review. Daniel received his MBA from Harvard Business School and holds degrees in Mechanical Engineering and Business from the California Institute of Technology. About Rejuvenate Bio: Rejuvenate Bio is a George Church spinout with backing from Merck and leading VCs developing one-time gene therapies that target the root causes of age-related disease, beginning in companion animals and expanding to humans. The company was the first to demonstrate lifespan extension using epigenetic reprogramming and is advancing a breakthrough cardiovascular platform built around a single-dose therapy that restores youthful levels of a critical age-declining soluble protein. Preclinical data show reversal of heart damage and durable metabolic reset, positioning the program as a potential long-term alternative to chronic therapies such as GLP-1s. About Xcellerant Ventures: Xcellerant is a venture capital firm investing in innovative companies across healthcare, technology, defense, and other emerging industries.About Jetstream Venture Fund: Jetstream is an interval fund that provides investors access to venture opportunities across multiple stages, with a $5,000 minimum and no carried interest. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing jetstream@sweaterfunds.com or by visiting www.jvf.vc. Please read the prospectus carefully before investing. About Pitch Deck Analysis: Pitch Deck Analysis reviews your deck like an investor would, with scoring, feedback, and recommendations on what to improve before you pitch. Use code EntrepreneurRx for a free Founder Pack with five free runs.

On this wek's episode of WSJ's Take On the Week, host Miriam Gottfried and guest host Aaron Back, editor of WSJ's Heard on the Street, preview the upcoming employment and inflation releases in advance of the Federal Open Market Committee's September policy meeting. They analyze why these economic indicators will draw heightened focus under Federal Reserve Chairman Kevin Warsh. Then Miriam and Aaron dig into Nvidia's recent blowout earnings and whether we will see that echo in Broadcom's earnings this week. Next, Dan Rasmussen, founder and portfolio manager at Verdad Advisers, offers insight into the past year's small-cap stock surge following an extended period of underperformance relative to mega-caps. Rasmussen explains why private equity firms face a massive exit logjam from acquisitions of small companies due to inflated valuations. Finally, we ask Rasmussen: does value investing still work? This is WSJ's Take On the Week where co-hosts Telis Demos, writer for WSJ's Heard on the Street, and Miriam Gottfried, WSJ's investing and wealth management reporter, cut through the noise and dive into markets, the economy and finance—the big trades, key players and business news ahead. Have an idea for a future guest or episode? How can we better help you take on the week? We'd love to hear from you. Email the show at takeontheweek@wsj.com. To watch the video version of this episode, visit our WSJ Podcasts YouTube channel or the video page of WSJ.com Further Reading Inflation Was 3.4% in July, Down Slightly From the Previous Month Fed's Preferred Inflation Gauge Remains Above Target Range Nvidia Reports Blowout Quarter, Says Demand for AI Chips Is Getting Even Hotter Nvidia's $279 Billion Supply-Chain Gamble Nvidia Has Become a Banker to the AI Boom, Putting It on Dangerous Ground Private-Equity Firms Are Sitting on a Nine-Year Backlog A Better Mousetrap for Buying Small Stocks Moderna Shares More Than Double on Success of mRNA Cancer Vaccine For more coverage of the markets and your investments, head to WSJ.com, WSJ's Heard on The Street Column, and WSJ's Live Markets blog. Sign up for the WSJ's free Markets A.M. newsletter. Follow Miriam Gottfried here and Telis Demos here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

A battle erupts between RFK Jr. and Pennsylvania Governor Josh Shapiro over two “measles-associated” deaths, vaccine misinformation, and the use of abortion-derived fetal cell lines in MMR production.Jefferey Jaxen investigates Merck's claim that fulfilling President Trump's order to split the MMR vaccine could take up to a decade. Plus, Fauci launches a legal defense fund as scrutiny of the COVID lab-leak cover-up intensifies.As closing arguments conclude in the Lindsay Clancy trial, Del sits down with board-certified clinical psychologist Dr. Roger McFillin to examine Clancy's psychiatric-drug history and ask whether the pharmaceutical industry belongs on trial, too.Then, Del checks in with MAPS President Dr. James Neuenschwander about a MAPS physician's appointment to the NIH and the upcoming MAPS conference.Guests: Aaron Siri, Esq., James Neuenschwander, M.D., Roger K. McFillin, Psy.D., ABPPAirdate: August 27, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

P.M. Edition for Aug. 26. Tech reporter Meghan Bobrowsky tells us why the Meta settlement could change how teenagers use some of the world's most popular apps. Plus, the FDA approves a milestone therapy for pancreatic cancer. WSJ reporter Xavier Martinez discusses how the nearly $40,000-a-month drug from Revolution Medicines could change patient outcomes of one the deadliest cancers. And the FBI shuts down a sprawling hacking network linked to China that targeted NASA, the Federal Reserve and critical infrastructure. Sabrina Siddiqui hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Brainstorm, Sam, Nick, and Brett break down Merck and Moderna's positive Phase 3 results for a personalized mRNA cancer vaccine, a treatment custom-built from each patient's own tumor that cut mortality from advanced melanoma by roughly 50% versus the standard of care. The team digs into cost, manufacturing scale, and why the capital poured into mRNA during COVID may be paying off in oncology. Then Brett reports back from a weekend with Grok Bot, which recovered $75 of his wife's forgotten escrow money on its first task, and the team debates why multiplayer agents could be the real threat to Microsoft's enterprise moat.Key Points From This Episode:How a custom mRNA vaccine trains the immune system against a patient's own tumor, and what Phase 3 melanoma results could mean for other cancersWhy $200K–$300K per treatment limits early use, and what we believe has to change for personalized oncology to scaleWhy agents that live inside team chat, not one-on-one, may be the real disruption to Microsoft and SlackIf you know ARK, you know we focus on long-term innovation. But that doesn't mean we ignore breaking news. Every day, we debate the latest developments in tech and markets. Now, we're bringing those conversations to you in “The Brainstorm,” a co-production from ARK, WOLF, and Public. Tune in weekly for our quick takes on what's shaping innovation right now.Learn more about WOLF: https://wolf.financialLearn more about Public: https://public.com/Disclosure: http://arkinv.st/39rzF94

Dr. Victoria Weston, MD, Associate Chief Medical Officer, Northwestern Medicine Immediate Care, joins John Williams to talk about Moderna and Merck saying an experimental vaccine prevented the return and spread of cancer in high-risk melanoma patients, a new weight loss drug that may burn fat without muscle loss, and what we should know about flu […]

On today's episode: Personlized cancer vaccines are coming! This worm can eat plastic! All that and more today on All Around Science...RESOURCESBobby was on Daily Tech News ShowModerna Press ReleaseNew Cancer Vaccine Could Change America in 7 Surprising Ways | NewsweekModerna, Merck breakthrough could usher in wave of cancer vaccines | CNNModerna, Merck unveil mRNA-based cancer vaccine that cuts spread | Al-JazeeraNature's original bioplastic is food for animalsCREDITS:Writing - Bobby Frankenberger & Maura ArmstrongBooking - September McCrady THEME MUSIC by Andrew Allenhttps://twitter.com/KEYSwithSOULhttp://andrewallenmusic.com Hosted on Acast. See acast.com/privacy for more information.

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the vaccine's prospects and the broader implications. The analysts also discuss Roche/Genentech's deal with Hanmi, which will add to the MNC's obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that has revived questions of the agency's independence.View full story: https://www.biocentury.com/article/660596#CancerVaccines #Obesity #FDA #Oncology #DrugDevelopment00:00 - Introduction03:03 - Moderna11:12 - Genentech obesity deal15:08 - Trump's FDA pickTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Why does the immune system cause inflammation in Crohn's disease and ulcerative colitis? And what do the gut microbiome, intestinal lining, and genetics have to do with inflammatory bowel disease (IBD)? In this episode of the Gastro Girl Podcast, host Jacqueline Gaulin talks with gastroenterologist and IBD expert Dr. Colleen Kelly about the important connection between the gut and immune system in IBD. Dr. Kelly explains how Crohn's disease and ulcerative colitis are immune-mediated diseases, why the immune system becomes involved in intestinal inflammation, and how interactions among the immune system, gut lining, genetics, and the trillions of microorganisms that make up the gut microbiome may contribute to IBD. You'll learn: How the immune system and digestive tract normally work together What happens to the immune response in IBD Why inflammation develops in Crohn's disease and ulcerative colitis How the intestinal barrier, or gut lining, fits into the picture What scientists understand about the gut microbiome and IBD Why IBD involves much more than digestive symptoms How understanding the biology of IBD can help you have more informed conversations with your healthcare team Whether you've recently been diagnosed with Crohn's disease or ulcerative colitis, are living with IBD, or are supporting someone who is, this patient-focused conversation provides an accessible foundation for understanding what is happening inside the body and why it matters for managing IBD. This educational initiative is sponsored by Merck.  

Dave Collum is the Betty R. Miller Professor of Chemistry at Cornell University. He earned his BS from Cornell and PhD from Columbia, then spent over 40 years at Cornell leading research in organolithium chemistry and serving in major departmental leadership roles, with collaborations at companies like Merck and Pfizer. He is also known for his sharp, contrarian annual Year in Review essays on markets, politics, and culture.Cornerstone Forum 26'https://shaunnewmanpodcast.substack.com/Silver Gold Bull Links:Website: https://silvergoldbull.ca/Email: SNP@silvergoldbull.comText Grahame: (587) 441-9100Bow Valley Credit UnionBitcoin: www.bowvalleycu.com/en/personal/investing-wealth/bitcoin-gatewayEmail: welcome@BowValleycu.com Get your voice heard: Text Shaun 587-217-8500

Dr. Victoria Weston, MD, Associate Chief Medical Officer, Northwestern Medicine Immediate Care, joins John Williams to talk about Moderna and Merck saying an experimental vaccine prevented the return and spread of cancer in high-risk melanoma patients, a new weight loss drug that may burn fat without muscle loss, and what we should know about flu […]

What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In his weekly clinical update, Daniel Griffin and Vincent Racaniello are perplexed by the state of global public health as malaria, cholera and other infectious diseases are spread by civil warfare, the lack of manpower at the CDC to implement Congressional health programs, the first cancer mRNA vaccine resulting from a Merck and Moderna collaboration, how cyclosporiasis and screwworm outbreaks continue, FDA approval of new drugs against screwworm and critical policy decisions to control the Ebola outbreak in the Congo, before Dr. Griffin deep dives into the measles outbreak, recent statistics on RSV, influenza, SARS-CoV-2 infections and the drop in vaccination rates in the US, how schools are the source of measles infection, how vaccines only prevent severe disease not transmission as trafficking of measles on vaccinated people begins to be acknowledged, to access and pay for Paxlovid, what to know about the mRNA flu vaccine, where to go for answers about long COVID-19, clinical guidelines for treating long COVID, three myths of respiratory disease and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Myanmar's Civil War Pushes Infectious Disease Over Its Borders (NY Times) Alzheimer's disease (AP News) US adult cigarette smoking rate hits another all-time low (AP News) The CDC has zombie programs. Congress funds them, but few people are left to do the work (AP News) Merck, Moderna's personalized cancer vaccine slows recurrence in phase 3, setting up approval push (FIERCE Biotech) Surveillance of Cyclosporiasis (CDC: Cyclosporiasis) Infectious DiseaseOutbreaks (Michigan: Health & Human Services) Cyclosporiasis Cases in North Carolina (North Carolina: Division of Public Health) Cyclospora Infection (Cyclosporiasis) (NYC Health) Missouri Communicable Disease Report (2026) (Missouri Health) TWiP 285: Why is cyclospora hard to contain: Parasitologists explain the 2026 US outbreak (microbeTV:TWiP) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newsroom) FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies (FDA) FDA grants emergency use authorization for another New World screwworm treatment (CIDRAP) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Three Months into the Bundibugyo Ebola Outbreak: Now is the time for Decisive Action (AfricaCDC) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Do vaccinated cases transmit measles? A systematic review and meta-analysis (Expert Review of Vaccines) County, district and community-level measles transmission in the United States in 2013−2025 (Nat Medicine) Dozens of States Tried to Roll Back Vaccine Laws. Here's How They Fared. (NY Times) More U.S. Parents Opting Children Out of Vaccine Requirements, C.D.C. Reports (NY Times) The threat of more, expanded measles outbreaks looms with start of school (CIDRAP) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) What to Know About the mRNA Flu Vaccine, Newly Approved by the FDA (JAMA) Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial (LANCET) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis (LANCET) A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study (LANCET) Real-world studies show RSV immunizations protect newborns in their first year of life (CIDRAP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Trump Officials Falsely Connect Covid Vaccines to Miscarriage (NY Times) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Beyond the acute illness: three myths about viral respiratory infection (JID) Reaching out to US house representative Letters read on TWiV 1350 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Moderna stock surged over 160% after their personalized mRNA cancer vaccine intismeran, combined with Merck's Keytruda, reported a successful trial for melanoma. But after the COVID-19 vaccine debacle, can mRNA technology be trusted? Salty Cracker joins Dr. Drew LIVE to discuss the new mRNA cancer treatment, ex Dr. Fauci adviser David Morens pleading guilty to conspiracy, the now-over-$900k GoFundMe for accused murderer Lindsay Clancy (allegedly benefiting her parents), and Roysha / Royce White's WNBA draft bid. Salty Cracker is an uncensored clown world commentator known for breaking the Left with satire, shame, and ridicule. He is active on Rumble as TheSaltyCracker. Follow at https://x.com/saltycracker9 「 SUPPORT OUR SPONSORS 」 • BIOPRO - BioPro+® is a natural formula of growth factors and peptides that support how you look, feel & perform. Learn more at ⁠⁠⁠https://drdrew.com/biopro⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • CHAPTER - For free and unbiased Medicare help, dial (218) 521-2472 to speak with my trusted partner, Chapter, or go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://askchapter.org/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan's contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don't directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (8/21/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7cb2wc","div":"rumble_v7cb2wc"}); Source Links (In Chronological Order): Sam Husseini Interview - Can A Corrupt System Be Changed From Within? New Tab (20) Brian Cates - Political Columnist & Pundit on X: "@L08818 I slowly came to realize on hanging out with Ron Paul enthusiasts that they don't want to reform the system, drive out the corruption, and restore the country. The want to...and they told me this several times, but back then I didn't really believe them...BURN IT ALL DOWN AND" / X (20) The Last American Vagabond on X: "What an absolutely disingenuous coward you are @L08818. https://t.co/31KRfbLcxZ" / X (20) SheThinksFreely (@L08818) / X (20) SheThinksFreely on X: "@TLAVagabond Bro GTFOH w this stupid sh*t Anarchy is anti American You traitorous piece of excrement" / X (20) SheThinksFreely on X: "

Israel's military has confirmed for the first time that its troops opened fire on a car carrying Hind Rajab, the five-year old Palestinian child who was killed alongside six of her relatives in Gaza in 2024. The IDF is opening a criminal investigation into the deaths, as well as those of two paramedics sent to rescue her. A separate inquiry will examine the killing of fifteen emergency and aid workers in Rafah last year. Also: after six years in the US state of California, Prince Harry and his family are moving back to the UK, but will not be undertaking royal duties. At least five people have been killed by Russian missile attacks on Kyiv in the early hours of Thursday morning. The US pharmaceutical giants, Moderna and Merck, say trials of an experimental treatment for melanoma have shown signs of success. US public debt has soared to a record 40 trillion dollars. A former Meta employee, turned whistleblower, tells a court in California that Meta CEO, Mark Zuckerberg, put growth in Facebook and Instagram before child safety. We have a special report about the gold rush in Kenya that's causing security and safety concerns. Scientists say giant whales are taking advantage of the ice disappearing from East Greenland, and shares in the Chinese robot maker, Unitree, soar as it launches its new humanoid robots.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Five-year-old Hind Rajab who was killed in Gaza, January 29th 2004, by the Israel Defense Forces (IDF) during the Gaza war. Credit: Family

Today's Headlines: Trump spent yesterday morning showing off his new White House helipad and giving an unprompted infomercial for Scott's Miracle-Gro that spiked the company's stock — a useful distraction from reporting that his aide Natalie Harp, the Human Printer, worked at the White House for a year without a security clearance because she refused until Trump personally intervened. He also TACO'd again, the Canada tariffs Trump announced at 50% were paused before they went into effect because they're "probably going to make a deal," and the US national debt hit $40 trillion for the first time, doubling in a decade, so the economic situation is going great.Surprise! We've got some great news, an mRNA vaccine to prevent skin cancer from recurring was successful in clinical trials, with Moderna and Merck potentially launching commercially next year and with possible applications to other cancers. Violent crime also dropped nearly 10% in 2025, the largest single-year decline since the FBI started tracking in 1936, with murder down 18% and robbery down 18.5%, which is the kind of news that deserves more attention than it's getting. Now back to regularly scheduled shenanigans. The Army is offering soldiers four days off to play Grand Theft Auto 6 as a re-enlistment incentive, and at least 20 have signed up, which says something about both the state of military recruitment and the anticipation for GTA 6. Elon Musk is reportedly planning to spend $100-200 million on the midterms, with a focus on helping Ken Paxton win a Texas Senate seat — Paxton has raised $9 million to James Talarico's $69 million, so Elon's money is going to be doing a lot of heavy lifting. In primary results, Trump's preferred Wyoming governor candidate lost to an experienced state legislator, and Alaska's jungle primary produced a genuinely chaotic situation where two Dan Sullivans are running — the incumbent Republican senator and a retired schoolteacher who argues he's been Dan Sullivan longer, which is technically true. And finally, Harry and Meghan are reportedly moving back to the UK with Archie and Lilibet, not as working royals, which means those HRH titles are about to get a workout. Resources/Articles mentioned: WaPo: Trump shows off his new helipad, brags about construction projects MS Now: Trump aide Natalie Harp worked at the White House without security clearance for a year  Reuters: US could cut key tariffs as part of proposed Canada deal, source says CNBC: U.S. government debt passes $40 trillion, more than doubling in a decade Variety: US Army Offering Soldiers Four Days Off to Play 'GTA 6' if They Reenlist Axios: Moderna and Merck shares soar on mRNA cancer vaccine Axios: FBI: 2025 had biggest violent-crime drop in 90 years WaPo: 8 takeaways and surprises from Florida, Wyoming and Alaska primaries Wired: Elon Musk Is Expected to Point His Money Machine at Texas Politics AP News: Prince Harry and Meghan are returning to the UK with their children, British newspaper says** Subscribe to the Betches News Room and join the Morning Announcements group chat. Go to: betchesnews.substack.com Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

In part two of Red Eye Radio with Gary McNamara and Eric Harley, the two biggest issues that most people are concerned about are vaccines and data centers. An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year. Moderna shares more than doubled Wednesday, while Merck's stock hit an all-time high. Also data centers, the gigantic buildings that house the computing power behind the artificial intelligence boom, are wildly unpopular. A recent Gallup poll found that 7 in 10 Americans oppose one being built in their area. For more talk on the issues that matter to you, listen on radio stations across America Monday-Friday 12am-5am CT (1am-6am ET and 10pm-3am PT), download the RED EYE RADIO SHOW app, asking your smart speaker, or listening at RedEyeRadioShow.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode is presented by Create A Video – Artificial intelligence (and the data centers that make it possible) have helped a world-changing breakthrough in cancer treatment. So, according to the Romney Rule, this means if you oppose data center construction it means you support people dying of cancer. Sorry, but I don't make the rules.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-pete-kaliner-show--6946691/support.Subscribe to the podcast My preferred podcast platform: SpreakerAll the links to Pete's Prep are free!Get exclusive content here!Media Bias Check: GroundNews promo code!Advertising and Booking inquiries: Pete@ThePeteKalinerShow.com  

This week Merck (known as MSD in Europe) and Moderna announced that a personalised cancer vaccine had significantly improved the outcomes of melanoma patients. Is the era of the cancer vaccine, at last, upon us? What does that mean? Anne Willis, a cancer cell biologist at the Medical Research Council, joins us to discuss. In just a few weeks the Royal Society will be putting out the red carpet as the most coveted prize in non-fiction science is about to be awarded. We will be speaking weekly to the shortlisted authors for the Royal Society Trivedi Book Prize, and we are starting with Kit Chapman, author of the Age of Alchemy. Plus, Penny Sarchet has, like an alchemist of old, been scouring the most obscure texts and journals to bring us the latest science knowledge. Presenter: Tom Whipple Producers: Alex Mansfield, Tabitha Taylor Buck, Katie Tomsett, Keiran Manetta-Jones Editor: Ilan Goodman Production Co-ordinator: Jana Bennett-Holesworth

In this episode of The Canadian Investor Podcast, we break down another busy week of market news and earnings. We start with Moderna, whose stock more than doubled after the company announced positive late-stage trial results for its personalized mRNA cancer therapy developed with Merck. We discuss why the news matters for Moderna, why Merck also benefited, and why biotech investing can be so volatile. We then look at Canadian Tire’s latest quarter, including the strength at SportChek and Mark’s, the stabilization in its financial services segment, and the upcoming Triangle Rewards partnership with Tim Hortons. From there, we discuss Home Depot and Lowe’s, what their results say about the housing and renovation market, and why elevated interest rates continue to weigh on big-ticket home improvement spending. We also revisit Constellation Software after its latest earnings, including organic growth concerns, record capital deployment, and why the company says AI has not materially disrupted its business so far. Finally, we cover Air Canada’s quarter, rising airline costs, CoreWeave’s explosive AI infrastructure growth and balance sheet risk, and Klarna’s latest results after a sharp post-earnings selloff. Tickers discussed: MRNA, MRK, CTC.A.TO, HD, LOW, CSU.TO, AC.TO, CRWV, KLAR, AAPL Subscribe to Our New Youtube Channel! Check out our portfolio by going to Jointci.com Our Website Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Fiscal.ai for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

P.M. Edition for Aug. 19. Today the total U.S. debt passed $40 trillion. WSJ economics reporter Matt Grossman discusses what that means for how the government functions. Plus, a successful trial of a mRNA vaccine for melanoma could mean potential new treatments for a deadly cancer–and news of the trial results more than doubled Moderna's stock price. And the Federal Trade Commission says retailers have to let shoppers know when they're using their personal data to raise prices. Dave Michaels, who covers corporate law enforcement for the Journal, explains how personalized pricing works, and how the FTC is looking to rein it in. Alex Ossola hosts. How Governments in the U.S. and Europe Are Stalling the AI Buildout Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Yields and the dollar moving sharply lower after the U.S. Treasury pledged to step up debt buybacks. The traders debate whether the move just gave stocks the all-clear. Then, Mizuho's Jared Holz reacts to the huge moves higher in Moderna and Merck, after the pair's personalized cancer vaccine succeeded in a pivotal  trial. Plus, new signs OpenAI is falling behind Anthropic, Target delivers a bullseye for investors and a humanoid robot maker's massive Shanghai debut. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Moderna and Merck just posted the first successful late-stage trial of a personalized mRNA cancer vaccine, intismeran paired with Keytruda, cutting the return and spread of high-risk melanoma, and Erick Erickson spends the hour singing the praises of Big Pharma and taking apart the conspiracy that drug companies are hiding the cure for cancer. He […]

Merck and Moderna have announced that a new mRNA vaccine has succeeded in blocking the return of one of the deadliest cancers. Wall Street Journal reporter Xavier Martinez explains more about the trial and why its giving cancer researchers hope.Then, primaries are underway, and in many races, progressives are prevailing. David Hogg, a progressive Democrat and president of Leaders We Deserve, shares his thoughts on primary results and why he's pushing party leaders to go with younger candidates.And, during the devastating Eaton fire in California, Nikki High turned her bookstore in Pasadena into a hub for mutual aid. High talks about the lessons she learned about community and resistance during that time.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

The Nasdaq, S&P 500, and Dow all rose roughly a fifth of a percent. Plus: Moderna stock skyrocketed nearly 177% after an experimental vaccine's success in a study. Pierre Bienaimé hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Target's second-quarter sales suggest the retailer's turnaround is working. And Cantor Fitzgerald plans to give its hedge-fund clients access to Kalshi's prediction markets. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shares of Moderna and Merck are surging on positive results from a Phase 3 trial of a groundbreaking cancer treatment. After a decade in development, individualized mRNA “vaccines” and established cancer treatment Keytruda result in reduced risk of recurrence or death. Moderna CEO Stephane Bancel and Merck Research Laboratories president Dr. Dean Li discuss this pivotal moment in medicine and how it fits into the long term visions for both Merck and Moderna. CEO of design and coding platform Figma Dylan Field discusses his company's wild year as a public company and building public trust in AI. Plus, it was primary night for Democrats in Florida, investors are scrutinizing revenues from Anthropic and OpenAI, and shares of Unitree are surging in Shanghai, presenting a potential challenge to U.S.-based humanoid robotics.    Stephane Bancel & Dr. Dean Li - 15:13 Dylan Field - 33:35   In this episode: Dylan Field, @zoink Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Katie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As shares of Moderna and Merck surge on new vaccine trial data, we speak to a top analyst about why he thinks the move higher is very difficult to rationalize. Then, Former CEA Chair Jason Furman discusses the Treasury Department's new debt buyback operations. Plus, we bring you the details of Chinese robotics company Unitree soaring in its public debut in Shanghai. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bond yields pull back after the Treasury doubles liquidity support for buybacks. Allianz's Mohamed El-Erian warns the recent turmoil could have big social and political consequences. Plus, Moderna and Merck rally on a major breakthrough for their skin cancer vaccine. And defense tech firm Lyntris makes its NYSE debut in a downsized IPO, with its CEO joining us to discuss the road ahead. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

One day after the 30-year yield hit fresh 2007 highs — and stocks extended their daily losing streak to three — Carl Quintanilla, Jim Cramer and David Faber led off the show with yields falling after the Treasury Department announced it would at least double the size of its government debt repurchases. The anchors delved into all things AI — from OpenAI reportedly lagging behind Anthropic on revenue growth, to midterm elections being impacted by the backlash against data centers. Moderna shares doubled and Merck shares rose sharply on late-stage trial results involving the companies' melanoma vaccine. Also in focus: Why Marvell shares surged; Toll Brothers beats; Reaction to retail earnings from the likes of Target, Lowe's and TJX.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

About this episode:   This summer, Merck & Co. settled more than 200 lawsuits alleging that the company's HPV vaccine, Gardasil, caused cases of autoimmune conditions and fertility issues in young women. But that $50 million settlement is not an admission of fault on the part of the company or the vaccine. In this episode: Vaccine law expert Dorit Reiss details the lawsuits, including why evidence isn't stacking up for plaintiffs and how headlines about the dollar amount can misconstrue the facts of the case.   Guest:  Dorit Reiss, PhD, is an expert on vaccine policy and a professor of law at UC San Francisco. Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Merck to Settle Bulk of Gardasil Suits for About $50 Million—Bloomberg Kennedy played key role in Gardasil vaccine case against Merck—Reuters What VAERS Is (And Isn't)—Johns Hopkins Bloomberg School of Public Health The HPV Vaccine, 20 Years Later—Public Health On Call (August 2026) Vaccines 101: The Vaccine Injury Compensation Program—Public Health On Call (February 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.